Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions

Bone Marrow Transplantation volume 46, pages 475–484 (2011)Cite this article

Subjects

Abstract

TBI has been used widely in the setting of BMT over the past 3 decades. Early research demonstrated feasibility and efficacy in the myeloablative setting, in preparation first for allogenic BMT and later for autologous stem cell rescue. As experience with TBI increased, its dual roles of myeloablation and immunosuppression came to be recognized. Toxicity associated with myeloablative TBI remains significant, and this treatment is generally reserved for younger patients with excellent performance status. Reduced intensity conditioning regimens may be useful to provide immunosuppression for patients who are not candidates for myeloablative treatment. Efforts to reduce toxicity through protection of normal tissue using methods of normal tissue blocking and use of TLI, rather than TBI, continue. In the future, modalities such as helical tomotherapy, proton radiotherapy and radioimmunotherapy, may have roles in delivery of radiation to the BM and lymphoid structures with reduced normal tissue toxicity. With further investigation, these efforts may expand the therapeutic ratio associated with TBI, allowing safer delivery to a broader range of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Nowell PC, Cole LJ, Habermeyer JG, Roan PL . Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res 1956; 16: 258–261.

    CAS  PubMed  Google Scholar 

  2. Vos O, Davids JAG, Weyzen WWH, van Bekkum DW . Evidence for cellular hypothesis in radiation protection by bone marrow cells. Acta Physiol Pharmacol Neerland 1956; 4: 482–486.

    CAS  Google Scholar 

  3. Lindsley DL, Odell TT, Tausche FG . Implantation of functional erythropoietic elements following total-body irradiation. Proc Soc Exp Biol Med 1955; 90: 512–515.

    Article  CAS  PubMed  Google Scholar 

  4. Makinodan T . Circulating rat cells in lethally irradiated mice protected with rat bone marrow. Proc Soc Exp Biol Med 1956; 92: 174–179.

    Article  CAS  PubMed  Google Scholar 

  5. Barnes DWH, Corp MJ, Loutit JF, Neal FE . Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. Br Med J 1956; 2: 626–627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mathé G, Amiel JL, Schwarzenberg L, Catton A, Schneider M . Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965; 25: 1525–1531.

    PubMed  Google Scholar 

  7. Andrews GA . Criticality accidents in Vinca, Yugoslavia, and Oak Ridge, Tennessee. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 56–74.

    CAS  PubMed  Google Scholar 

  8. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843, 895–902.

    Article  CAS  PubMed  Google Scholar 

  9. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511–533.

    CAS  PubMed  Google Scholar 

  10. Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–599.

    Article  CAS  PubMed  Google Scholar 

  11. Thomas ED, Sanders JE, Flournoy N, Johnson FL, Buckner CD, Clift RA et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 1979; 54: 468–476.

    CAS  PubMed  Google Scholar 

  12. Keane TJ, Van Dyk J, Rider WD . Idiopathic interstitial pneumonia following bone marrow transplantation: the relationship with total body irradiation. Int J Radiat Oncol Biol Phys 1981; 7: 1365–1370.

    Article  CAS  PubMed  Google Scholar 

  13. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428–1434.

    Article  CAS  PubMed  Google Scholar 

  14. Vaidya SJ, Atra A, Bahl S, Pinterton CR, Calvagna V, Horton C et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: long-term follow-up. Bone Marrow Transplant 2000; 25: 599–603.

    Article  CAS  PubMed  Google Scholar 

  15. Dusenberry KE, Daniels KA, McClure JS, McGlave PB, Ramsay NK, Blazar BR et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995; 31: 119–128.

    Article  Google Scholar 

  16. Biagi E, Rovelli A, De Lorenzo P, Uderzo C . Autologous hematopoetic stem cell transplantation (AHSCT) as consolidation therapy for childhood acute myelogenous leukemia in 1st complete remission. Pediatr Hematol Oncol 2001; 18: 359–362.

    Article  CAS  PubMed  Google Scholar 

  17. Ringdén O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R et al. A comparison of Busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637–645.

    Article  PubMed  Google Scholar 

  18. Davies SM, Ramsay KC, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.

    Article  CAS  PubMed  Google Scholar 

  19. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001; 27: 349–354.

    Article  PubMed  Google Scholar 

  20. Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T . Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51 (1): 50–60.

    Article  PubMed  Google Scholar 

  21. Altschuler C, Resbeut M, Blaise D, Maraninchi D, Stoppa AM, Lagrange JL et al. Fractionated total body irradiation and bone marrow transplantation in acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1990; 19: 1151–1154.

    Article  CAS  PubMed  Google Scholar 

  22. Gale RP, Butturini A, Bortin MM . What does total body irradiation do in bone marrow transplants for leukemia? Int J Radiat Oncol Biol Phys 1991; 20: 631–634.

    Article  CAS  PubMed  Google Scholar 

  23. Gough MJ, Crittenden MR . Combination approaches to immunotherapy: the radiotherapy example. Immunotherapy 2009; 1 (6): 1025–1037.

    Article  PubMed  Google Scholar 

  24. Kim TH, Rybka WB, Lehnert S, Podgorsak EB, Freeman CR . Interstitial pneumonitis following total body irradiation for bone marrow transplantation using two different dose rates. Int J Radiat Oncol Biol Phys 1985; 11: 1285–1291.

    Article  CAS  PubMed  Google Scholar 

  25. Barrett AJ . Bone marrow transplantation. Cancer Treat Rev 1987; 14: 203–213.

    Article  CAS  PubMed  Google Scholar 

  26. Barrett AJ, Depledge MH, Powles RL . Interstitial pneumonitis following bone marrow transplantation after low dose rate total body irradiation. Int J Radiat Oncol Biol Phys 1983; 9: 1029–1033.

    Article  CAS  PubMed  Google Scholar 

  27. Cosset JM, Girinsky T, Malaise E, Chaillet MP, Dutreix J . Clinical basis for TBI fractionation. Radiother Oncol 1990; 18 (Suppl 1): 60–67.

    Article  PubMed  Google Scholar 

  28. Shank B, Chu FC, Dinsmore R, Kapoor N, Kirkpatrick D, Teitelbaum H et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9: 1607–1611.

    Article  CAS  PubMed  Google Scholar 

  29. Thomas ED, Clift RA, Hersman J, Sanders JE, Stewart P, Buckner CD et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982; 8: 817–821.

    Article  CAS  PubMed  Google Scholar 

  30. Katz R, Sharma SC, Homayoonfar M . Irradiation equivalence. Health Phys 1972; 23: 740–741.

    CAS  PubMed  Google Scholar 

  31. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD et al. Allogeneic bone marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871.

    CAS  PubMed  Google Scholar 

  32. Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, Thomas ED . Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 1998; 92: 1455–1456.

    CAS  PubMed  Google Scholar 

  33. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB et al. Allogeneic marrow transplantationin patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660–1665.

    CAS  PubMed  Google Scholar 

  34. Bieri S, Helg C, Chapuis B, Miralbell R . Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 2001; 18: 1071:1077.

    Google Scholar 

  35. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  PubMed  Google Scholar 

  36. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  37. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.

    Article  CAS  PubMed  Google Scholar 

  38. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    Article  CAS  PubMed  Google Scholar 

  39. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorrer M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993–2003.

    Article  PubMed  Google Scholar 

  40. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744–2748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 272–279.

    Article  PubMed  Google Scholar 

  42. Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116: 366–374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Pecego R, Hill R, Appelbaum FR, Amos D, Buckner CD, Fefer A et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515–517.

    Article  CAS  PubMed  Google Scholar 

  44. Deeg HJ . Delayed complications and long-term effects after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 641–657.

    Article  CAS  PubMed  Google Scholar 

  45. Benyunes MC, Sullivan KM, Deeg HJ, Mori M, Meyer W, Fisher L et al. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys 1995; 32: 661–670.

    Article  CAS  PubMed  Google Scholar 

  46. Tauchmanovà L, Selleri C, DeRosa G, Pagano L, Orio F, Lombarde G et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002; 95: 1076–1084.

    Article  PubMed  Google Scholar 

  47. Gerstein J, Meyer A, Sykora KW, Frühauf J, Karstens JH, Bremer M . Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT). Strahlenther Onkol 2009; 185: 751–755.

    Article  PubMed  Google Scholar 

  48. Abboud I, Porcher R, Robin M, de Latium RP, Glotz D, Socié G et al. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1251–1257.

    Article  CAS  PubMed  Google Scholar 

  49. Benmiloud S, Steffens M, Beauloye V, de Wandeleer A, Devogelaer JP, Brichard B et al. Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-hodgkin lymphoma during childhood. Horm Res Paediatr 2010; 74: 241–250.

    Article  CAS  PubMed  Google Scholar 

  50. Brand HS, Bots CP, Raber-Durlacher JE . Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation. Br Dent J 2009; 207: E17.

    Article  CAS  PubMed  Google Scholar 

  51. Ishida Y, Sakamoto N, Kamibeppu K, Kakee N, Iwai T, Ozono S et al. Late effects and quality of life of childhood cancer survivors: Part 2. Impact of radiotherapy. Int J Hematol 2010; 92 (1): 95–104.

    Article  PubMed  Google Scholar 

  52. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE et al. Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant 2010 (e-pub ahead of print).

  53. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699–1706.

    Article  CAS  PubMed  Google Scholar 

  54. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112 (12): 4425–4431.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Carreras E . Veno-occlusive disease of the liver after hematopoetic cell transplantation. Eur J Haematol 2000; 64 (5): 281–291.

    Article  CAS  PubMed  Google Scholar 

  56. Kusumi E, Kami M, Kanda Y, Murashige N, Seki K, Fujiwara M . Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. Biol Blood Marrow Transplant 2006; 12: 1302–1309.

    Article  PubMed  Google Scholar 

  57. Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoetic cell transplantation. Blood 2009; 113: 1175–1183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socié G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997; 336 (13): 897–904.

    Article  CAS  PubMed  Google Scholar 

  59. Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.

    Article  PubMed  Google Scholar 

  60. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593.

    CAS  PubMed  Google Scholar 

  61. Janssen WJ, Muldrow A, Kearns MT, Barthel L, Henson PM . Development and characterization of a lung-protective method of bone marrow transplantation in the mouse. J Immunol Methods 2010; 357: 1–9.

    Article  CAS  PubMed  Google Scholar 

  62. Singh AK, Karimpour SE, Savani BN, Guion P, Hope AJ, Mansueti JR et al. Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant. Int J Radiat Oncol Biol Phys 2006; 66 (2): 520–527.

    Article  PubMed  Google Scholar 

  63. van Kempen-Harteveld ML, van Weel-Sipman MH, Emmens C, Noordijk EM, van der Tweel I, Révész T et al. Eye shielding during total body irradiation for bone marrow transplantation in children transplanted for a hematological disorder: risks and benefits. Bone Marrow Transplant 2003; 31: 1151–1156.

    Article  CAS  PubMed  Google Scholar 

  64. Broerse JJ, Dutriex A, Noordijk EM . Physical, biological, and clinical aspects of TBI. Radiother Oncol 1990; 18 (Suppl 1): 11–162.

    Google Scholar 

  65. Harden SV, Routsis DS, Geater AR, Thomas SJ, Coles C, Taylor PJ et al. Total body irradiation using a modified standing technique: a single institution 7 year experience. Br J Radiol 2001; 74: 1041–1047.

    Article  CAS  PubMed  Google Scholar 

  66. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S . Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: ‘natural suppressor’ cells. J Immunol 2001; 167: 2087–2096.

    Article  CAS  PubMed  Google Scholar 

  67. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S . Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003; 9: 355–363.

    Article  PubMed  Google Scholar 

  68. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S . Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389–399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA et al. Protective conditioning for acute graft-versus-host disease. New Engl J Med 2005; 353 (13): 1321–1331.

    Article  CAS  PubMed  Google Scholar 

  70. Schaenman JM, Shashidhar S, Rhee C, Wong J, Navato S, Wong RM et al. Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoetic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol Blood Marrow Transplant 2010 (e-pub ahead of print).

  71. Nakamae H, Terada Y, Nakane T, Koh H, Nakamae M, Aimoto R et al. A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia. Gan To Kagaku Ryoho 2010; 37: 1691–1695.

    PubMed  Google Scholar 

  72. Zhuang AH, Liu A, Schultheiss T, Wong YC . Dosimetric study and verification of total body irradiation using helical tomotherapy and its comparison to extended SSD technique. Medical Dosimetry (e-pub ahead of print).

  73. Wong JY, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant 2006; 12: 306–315.

    Article  PubMed  Google Scholar 

  74. Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005; 63: 362–372.

    Article  PubMed  Google Scholar 

  75. Timmermann B, Lomax AJ, Nobile L, Grotzer MA, Weiss M, Kortmann RD et al. Novel technique of craniospinal axis proton therapy with the spot-scanning system: avoidance of patching multiple fields and optimized ventral dose distribution. Strahlenther Onkol 2007; 183: 685–688.

    Article  PubMed  Google Scholar 

  76. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 2010; 116 (10): 1795–1802.

    Article  CAS  PubMed  Google Scholar 

  77. Barbet J, Chatal JF, Kraeber-Bodéré F . Radiolabeled antibodies for cancer treatment. Med Sci (Paris) 2009; 25: 1039–1045.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    C E Hill-Kayser, J P Plastaras, Z Tochner & E Glatstein

Authors
  1. C E Hill-Kayser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J P Plastaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z Tochner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Glatstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C E Hill-Kayser.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hill-Kayser, C., Plastaras, J., Tochner, Z. et al. TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant 46, 475–484 (2011). https://doi.org/10.1038/bmt.2010.280

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.280

Keywords

This article is cited by

Search

Advanced search

Quick links